Dr. Chang on Genomic Testing in Breast Cancer

Jenny C. Chang, MD
Published: Wednesday, Jan 25, 2017



Jenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.

The complex nature of breast cancer management is growing due to the number of tests available in the modern age. Within each subtype, there are even smaller groups that make it more arduous to test for therapy benefit, such as in triple-negative breast cancer, which has at least 6 subtypes.

Chang suggests that genomic testing could be beneficial, as it is simply a painless blood test that can find mutations, circulating tumor cells, and cell-free DNA.

Rather than testing patients with a collection of different tests with the hope of finding a response, Chang suggests that the oncology community could be a little more thoughtful in the types of tests they order.
 


Jenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.

The complex nature of breast cancer management is growing due to the number of tests available in the modern age. Within each subtype, there are even smaller groups that make it more arduous to test for therapy benefit, such as in triple-negative breast cancer, which has at least 6 subtypes.

Chang suggests that genomic testing could be beneficial, as it is simply a painless blood test that can find mutations, circulating tumor cells, and cell-free DNA.

Rather than testing patients with a collection of different tests with the hope of finding a response, Chang suggests that the oncology community could be a little more thoughtful in the types of tests they order.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x